Literature DB >> 1347413

Dopaminergic transplants normalize amphetamine- and apomorphine-induced Fos expression in the 6-hydroxydopamine-lesioned striatum.

M A Cenci1, P Kalén, R J Mandel, K Wictorin, A Björklund.   

Abstract

Dopamine receptor-mediated Fos protein expression in the striatum has been used to monitor dopamine receptor activation at the cellular level after dopaminergic denervation and reinnervation by fetal nigral transplants. The pattern of striatal Fos expression after systemic administration of either the dopamine receptor agonist, apomorphine, or the dopamine-releasing agent, amphetamine, was studied in rats which had received cell suspension grafts of fetal ventral mesencephalic neurons into the striatum after a complete 6-hydroxydopamine lesion of mesostriatal dopaminergic projection. Grafted animals, and normal and lesioned controls were killed 2 h after administration of either D-amphetamine (5 mg/kg, i.p.) or apomorphine (0.25 mg/kg, s.c.). Fos protein was detected immunohistochemically, and the density of Fos-immunoreactive cell nuclei was measured in 12 selected areas of caudate-putamen, nucleus accumbens and globus pallidus by computerized image analysis. Consistent with previous studies, amphetamine induced high Fos expression in the medial and dorsal parts of the intact caudate-putamen and significantly lower expression in the denervated caudate-putamen. A significant difference between lesioned and intact striata was present also in globus pallidus, but not in nucleus accumbens. In grafted rats, amphetamine-induced Fos activation was restored to normal or supranormal levels in the anterior and central caudate-putamen (i.e. close to the graft deposits), whereas in the tail of caudate-putamen Fos expression was significantly lower than normal. The side-to-side difference in globus pallidus seen in lesioned rats was no longer present in the grafted animals. Apomorphine led to high Fos activation throughout the dopamine-depleted caudate-putamen, whereas only very few immunopositive cells were observed in the intact caudate-putamen. Also in globus pallidus and nucleus accumbens, a significantly higher number of Fos-immunoreactive cells was detected on the denervated side. In the grafted rats, apomorphine-induced Fos activation was similar to normal in all striatal areas sampled, as well as in the globus pallidus. The graft-induced effect extended over a considerably larger area than that covered by the graft-derived tyrosine hydroxylase-immunoreactive innervation. These findings indicate that fetal ventral mesencephalic transplants normalize dopamine receptor-mediated function in the 6-hydroxydopamine-lesioned caudate-putamen and nucleus accumbens, as well as in a primary target of the striatal output neurons, the globus pallidus. The results support the idea that dopamine released from the grafted neurons, both under baseline conditions and after amphetamine administration, exerts functional effects over a larger volume of the striatum than that reached by the graft-derived fibers.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347413     DOI: 10.1016/0306-4522(92)90196-9

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  17 in total

1.  Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs.

Authors:  B E H Sumner; L A Cruise; D A Slattery; D R Hill; M Shahid; B Henry
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

2.  Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues.

Authors:  Anne-Marie Bédard; Jérôme Maheux; Daniel Lévesque; Anne-Noël Samaha
Journal:  Neuropsychopharmacology       Date:  2011-02-16       Impact factor: 7.853

3.  Time course of striatal changes induced by 6-hydroxydopamine lesion of the nigrostriatal pathway, as studied by combined evaluation of rotational behaviour and striatal Fos expression.

Authors:  J L Labandeira-Garcia; G Rozas; E Lopez-Martin; I Liste; M J Guerra
Journal:  Exp Brain Res       Date:  1996-02       Impact factor: 1.972

4.  Intrastriatal mesencephalic grafts affect neuronal activity in basal ganglia nuclei and their target structures in a rat model of Parkinson's disease.

Authors:  N Nakao; M Ogura; K Nakai; T Itakura
Journal:  J Neurosci       Date:  1998-03-01       Impact factor: 6.167

5.  Optogenetics enables functional analysis of human embryonic stem cell-derived grafts in a Parkinson's disease model.

Authors:  Julius A Steinbeck; Se Joon Choi; Ana Mrejeru; Yosif Ganat; Karl Deisseroth; David Sulzer; Eugene V Mosharov; Lorenz Studer
Journal:  Nat Biotechnol       Date:  2015-01-12       Impact factor: 54.908

6.  Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease.

Authors:  R J Mandel; K G Rendahl; S K Spratt; R O Snyder; L K Cohen; S E Leff
Journal:  J Neurosci       Date:  1998-06-01       Impact factor: 6.167

Review 7.  Moving stem cells to the clinic: potential and limitations for brain repair.

Authors:  Julius A Steinbeck; Lorenz Studer
Journal:  Neuron       Date:  2015-04-08       Impact factor: 17.173

8.  Striatal Fos expression is indicative of dopamine D1/D2 synergism and receptor supersensitivity.

Authors:  G J LaHoste; J Yu; J F Marshall
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

9.  The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease.

Authors:  Shane Grealish; Marie E Jönsson; Meng Li; Deniz Kirik; Anders Björklund; Lachlan H Thompson
Journal:  Brain       Date:  2010-01-31       Impact factor: 13.501

10.  Conditioning versus priming of dopaminergic grafts by amphetamine.

Authors:  L E Annett; P J Reading; D Tharumaratnam; D N Abrous; E M Torres; S B Dunnett
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.